Immuron achieves record quarterly Travelan® sales
Highlights:
- Record quarterly Travelan® sales of $1,550,240
- Total sales of A$1,565,767 in Q1, FY24
- $1,508,933 increase on Q1, FY23 sales
- 130% higher than pre-pandemic period Q1, FY20 sales
Melbourne, Australia, October 11, 2023: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.
Australia
Immuron previously reported (August 9, 2023) that short term stock outages of Travelan® in some wholesalers and pharmacies in the June 2023 quarter was resolved following receipt of GMP Clearance from the Therapeutic Goods Administration (TGA). Immuron has since supplied product to wholesalers who in turn have supplied retail pharmacies.
Sales of Travelan® increased to AUD $1,339,160 in Q1, FY24, compared to AUD $25,565 in Q1, FY23. Sales increased by $940,991 (236%) on the pre-pandemic peak period (Q1, FY20).
This increase partially reflects 3 months (May, June, July) of backorders accrued while awaiting GMP Clearance from the TGA.
Immuron anticipates continued demand for replenishment of Travelan® as retail pharmacies sell to consumers. Australian Bureau of Statistics: short term resident returns in July 2023 were 48% higher than July 2022 and approaching pre-pandemic levels (89% of July 2019)1. Cumulative short term resident returns in the 12 months to July 2023 were 77% of those in the pre-pandemic period 12 months to July 2019. 1
USA
Sales of Travelan® increased to AUD $211,080 in Q1, FY24, compared to AUD $16,614 in Q1, FY23. Sales were lower by $20,499 (-9%) on the pre-pandemic peak period (Q1, FY20).
International Trade Administration Total U.S. citizen international visitor departures from the United States in June 2023 increased 20.2% compared to June 2022 and were 99.4% of total departures in June 2019. 2
![Bullish](/static/images/ih2-bull.png)
Recent IMRN News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 01:28:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 12:00:02 PM
- Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® • GlobeNewswire Inc. • 08/16/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/07/2024 10:26:22 AM
- Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect • GlobeNewswire Inc. • 08/07/2024 10:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/22/2024 04:15:10 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 10:14:35 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/15/2024 12:00:09 PM
- Immuron announces record Travelan® sales globally, Australia and USA • GlobeNewswire Inc. • 07/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/09/2024 10:09:39 AM
- Immuron requests pre-IND meeting for IMM-529 with FDA filing • GlobeNewswire Inc. • 07/02/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/05/2024 10:12:05 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 12:00:38 PM
- Immuron Board Changes • GlobeNewswire Inc. • 05/31/2024 10:00:00 AM
- Immuron CEO Steven Lydeamore to present at Peak Sky High • GlobeNewswire Inc. • 05/31/2024 10:00:00 AM
- Immuron Director Resignation • GlobeNewswire Inc. • 05/03/2024 10:00:00 AM
- Immuron to host Live Virtual Event • GlobeNewswire Inc. • 04/15/2024 10:00:00 AM
- Immuron Travelan® sales continued strong growth • GlobeNewswire Inc. • 04/10/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:00:20 PM
- Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US • GlobeNewswire Inc. • 03/07/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 01:08:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/21/2024 01:00:38 PM
- Immuron Presentation Australian Biologics Festival 2024 • GlobeNewswire Inc. • 02/21/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 01:00:12 PM
- Immuron achieves record Travelan® sales • GlobeNewswire Inc. • 02/13/2024 11:00:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM